Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The HIV-1 Gag, Pol, Vif, and Nef proteins are critical viral gene products encoded by the HIV-1 genome, each fulfilling distinct functions essential to the viral replication cycle and pathogenesis[1][2][3][5].\n- Gag is the major structural polyprotein, involved in viral assembly, budding from the host cell, and formation of virus-like particles; upon cleavage, it yields matrix, capsid, nucleocapsid, and p6 proteins[1][2][6].\n- Pol is a polyprotein precursor encoding the enzymes protease, reverse transcriptase, and integrase, required for maturation, viral DNA synthesis, and genome integration, respectively—making it a major target of current antiretroviral drugs[2][7][8].\n- Vif is an accessory protein that protects the virus from the host restriction factor APOBEC3G and optimizes infectivity by stabilizing the viral nucleoprotein complex and modulating reverse transcriptase[3].\n- Nef is another accessory protein facilitating immune evasion (by downregulating host CD4 and MHC-I), enhancing replication efficiency, and is a key factor in HIV-1 pathogenicity[3][4].\nDespite overlapping involvement in the HIV life cycle, these proteins are biologically, structurally, and functionally distinct and are usually considered individually as targets for therapeutic or diagnostic development.
Inhibition of viral protease (prevents maturation, noninfectious particles)\nInhibition of reverse transcriptase (blocks synthesis of viral DNA)\nInhibition of integrase (preve`nts integration of viral genome into host DNA)\nGag inhibitors (maturation inhibitors) disrupt virion assembly\nExperimental approaches for Vif and Nef block immune evasion or viral replication enhancement
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on HIV-1 Gag, Pol, Vif, and Nef proteins (None, but commonly referenced as Gag, Pol, Vif, and Nef individually).